Usefulness of CHADS2 Score to Predict C-Reactive Protein, Left Atrial Blood Stasis, and Prognosis in Patients With Nonrheumatic Atrial Fibrillation

The CHADS2 score (congestive heart failure, hypertension, age >75 years, diabetes, and previous stroke/transient ischemic attack) is used for embolic risk stratification in patients with atrial fibrillation (AF). Although systemic inflammation is a known predictor of left atrial thrombus formatio...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2010-08, Vol.106 (4), p.535-538
Main Authors: Maehama, Tomoko, MD, Okura, Hiroyuki, MD, Imai, Koichiro, MD, Yamada, Ryotaro, MD, Obase, Kikuko, MD, Saito, Ken, MD, Hayashida, Akihiro, MD, Neishi, Yoji, MD, Kawamoto, Takahiro, MD, Yoshida, Kiyoshi, MD
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Atrial Fibrillation - blood
Atrial Fibrillation - complications
Biological and medical sciences
C-Reactive Protein - analysis
Cardiac arrhythmia
Cardiac dysrhythmias
Cardiology
Cardiology. Vascular system
Cardiovascular
Female
Heart
Heart Atria
Heart Diseases - etiology
Hemostasis
Humans
Inflammation - etiology
Male
Medical prognosis
Medical sciences
Middle Aged
Plasma
Predictive Value of Tests
Prognosis
Proteins
Rheumatic Heart Disease
Risk Assessment
Severity of Illness Index
Survival analysis
Thrombosis - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CHADS2 score (congestive heart failure, hypertension, age >75 years, diabetes, and previous stroke/transient ischemic attack) is used for embolic risk stratification in patients with atrial fibrillation (AF). Although systemic inflammation is a known predictor of left atrial thrombus formation in patients with nonrheumatic AF, the relation between the CHADS2 score and systemic inflammation is unknown. A total of 165 patients with nonrheumatic AF were enrolled and analyzed. According to the CHADS2 score, the study patients were grouped into low- (score 0 to 1), intermediate- (score 2 to 3), or high- (score 4 to 6) risk categories. The plasma C-reactive protein levels, transesophageal echocardiographic findings, and cardiovascular events (death, stroke, and heart failure) were compared. Patients in the high-risk group had significantly greater C-reactive protein levels than those in the intermediate- and low-risk groups (0.80 mg/dl, range 0.21 to 1.50, vs 0.16 mg/dl, range 0.06 to 0.50, vs 0.08 mg/dl, range 0.04 to 0.21, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2010.03.067